Can proton pump inhibitors (e.g., omeprazole, esomeprazole) cause palpitations in an adult patient taking a standard dose for gastritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can PPIs Cause Palpitations?

PPIs can cause palpitations indirectly through electrolyte disturbances (particularly hypomagnesemia) and potentially through direct cardiac effects, though palpitations are not listed as a common adverse effect in FDA labeling.

Direct Cardiac Effects

The FDA label for omeprazole lists cardiovascular adverse events including tachycardia, bradycardia, and palpitations as postmarketing reports 1. While these are documented, they occur rarely enough that the actual frequency cannot be reliably estimated from voluntary reporting.

Research demonstrates that PPIs can exert direct cardiac effects:

  • In vivo studies show PPIs can increase heart rate at low-to-moderate doses, with omeprazole and lansoprazole causing dose-dependent increases in heart rate and cardiac output 2
  • Isolated human myocardium studies reveal negative inotropic effects (reduced contractility) at therapeutic concentrations, though these were studied in failing hearts 3
  • PPIs can prolong QT intervals and affect cardiac repolarization, particularly at higher doses 2

Indirect Mechanisms: Electrolyte Disturbances

The more clinically relevant pathway for palpitations is through PPI-induced hypomagnesemia, which can trigger cardiac arrhythmias:

  • Long-term PPI use can cause severe hypomagnesemia (<0.5 mg/dL), often accompanied by hypokalemia and hypocalcemia 4
  • Hypomagnesemia increases risk of QT prolongation and potentially lethal ventricular arrhythmias 2
  • These electrolyte abnormalities may present with minimal symptoms initially but can manifest as palpitations

Clinical Approach

If a patient on standard-dose PPIs for gastritis reports palpitations:

  1. Check serum magnesium, potassium, and calcium levels - particularly if PPI use exceeds several months
  2. Assess for other cardiovascular symptoms - chest pain, syncope, or documented arrhythmias
  3. Review the indication for PPI therapy - patients without definitive indications should be considered for de-prescribing 5
  4. Consider dose reduction - if chronic therapy is needed, attempt step-down from twice-daily to once-daily dosing 5

Important Caveats

  • The FDA label documents palpitations as a postmarketing adverse event, but the causal relationship and frequency remain uncertain 1
  • Most patients tolerate PPIs without cardiac symptoms
  • Do not discontinue PPIs solely due to concern for adverse effects if a valid indication exists 5
  • For gastritis specifically, evaluate whether the patient truly requires ongoing PPI therapy or if the indication can be reassessed 5

The evidence suggests palpitations can occur with PPI use through both direct cardiac effects and electrolyte-mediated mechanisms, though this remains an uncommon adverse effect. Monitoring electrolytes in long-term users and reassessing the need for continued therapy represents the most prudent approach.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.